Jeffrey P. Mornhinweg

Array ( [id] => 13444741 [patent_doc_number] => 20180273913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => cDNA CLONE-LAUNCHED PLATFORM FOR HIGH-YIELD PRODUCTION OF INACTIVATED ZIKA VIRUS [patent_app_type] => utility [patent_app_number] => 15/897488 [patent_app_country] => US [patent_app_date] => 2018-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16503 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15897488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12842542 [patent_doc_number] => 20180172687 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => MULTIPLEX HEPATITIS B ASSAY [patent_app_type] => utility [patent_app_number] => 15/897040 [patent_app_country] => US [patent_app_date] => 2018-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7968 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15897040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14978339 [patent_doc_number] => 10443075 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-15 [patent_title] => Adeno-associated virus vector variants for high efficiency genome editing and methods thereof [patent_app_type] => utility [patent_app_number] => 15/894538 [patent_app_country] => US [patent_app_date] => 2018-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 95 [patent_figures_cnt] => 81 [patent_no_of_words] => 42124 [patent_no_of_claims] => 85 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 440 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15894538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14637143 [patent_doc_number] => 10363300 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-30 [patent_title] => FMDV and E2 fusion proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 15/888718 [patent_app_country] => US [patent_app_date] => 2018-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 18 [patent_no_of_words] => 13314 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15888718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15895373 [patent_doc_number] => 20200147205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => POLYPEPTIDE CARRIER FOR PRESENTING TARGET POLYPEPTIDE AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/484366 [patent_app_country] => US [patent_app_date] => 2018-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28347 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16484366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16761091 [patent_doc_number] => 20210106672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => METHOD FOR ADAPTING INFLUENZA VIRUSES TO VERO CELLS [patent_app_type] => utility [patent_app_number] => 16/960283 [patent_app_country] => US [patent_app_date] => 2018-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16960283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14637147 [patent_doc_number] => 10363302 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-30 [patent_title] => Influenza nucleic acid molecules and vaccines therefrom [patent_app_type] => utility [patent_app_number] => 15/865573 [patent_app_country] => US [patent_app_date] => 2018-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 16106 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15865573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13871365 [patent_doc_number] => 20190032023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => INFLUENZA VIRUS REPLICATION FOR VACCINE DEVELOPMENT [patent_app_type] => utility [patent_app_number] => 15/865364 [patent_app_country] => US [patent_app_date] => 2018-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21219 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15865364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14818375 [patent_doc_number] => 10406173 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-10 [patent_title] => Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer [patent_app_type] => utility [patent_app_number] => 15/862999 [patent_app_country] => US [patent_app_date] => 2018-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 14 [patent_no_of_words] => 21427 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15862999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14993753 [patent_doc_number] => 20190315834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => SIRP alpha-CD70 FUSION PROTEIN AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/475683 [patent_app_country] => US [patent_app_date] => 2018-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25502 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16475683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15020903 [patent_doc_number] => 20190321456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => COMPOSITIONS AND METHODS FOR ENHANCEMENT OF IMMUNE RESPONSES [patent_app_type] => utility [patent_app_number] => 16/475963 [patent_app_country] => US [patent_app_date] => 2017-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16475963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16843131 [patent_doc_number] => 11015205 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-25 [patent_title] => Oligomeric vaccines from plants by S-Tag-S-protein fusions [patent_app_type] => utility [patent_app_number] => 16/472802 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 8251 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16472802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17407158 [patent_doc_number] => 11248027 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Engineered outer domain (eOD) of HIV GP120, mutants and use thereof [patent_app_type] => utility [patent_app_number] => 15/844753 [patent_app_country] => US [patent_app_date] => 2017-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 144 [patent_figures_cnt] => 172 [patent_no_of_words] => 48004 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15844753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206528 [patent_doc_number] => 20200239518 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => MANUFACTURING OPTIMIZATION OF GL-2045, A MULTIMERIZING STRADOMER [patent_app_type] => utility [patent_app_number] => 16/467868 [patent_app_country] => US [patent_app_date] => 2017-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30688 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16467868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12625122 [patent_doc_number] => 20180100204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => ADENOVIRAL TUMOR DIAGNOSTICS [patent_app_type] => utility [patent_app_number] => 15/835892 [patent_app_country] => US [patent_app_date] => 2017-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14335 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15835892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13342809 [patent_doc_number] => 20180222944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION [patent_app_type] => utility [patent_app_number] => 15/833365 [patent_app_country] => US [patent_app_date] => 2017-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46911 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15833365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15035735 [patent_doc_number] => 20190328872 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => Viral Vector Constructs for Expression of Genetic Adjuvants Activating the STING Pathway [patent_app_type] => utility [patent_app_number] => 16/464492 [patent_app_country] => US [patent_app_date] => 2017-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9365 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16464492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14893977 [patent_doc_number] => 20190290754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => VACCINE COMPOSITION COMPRISING HEPATITIS B VIRUS-LIKE PARTICLE AS ADJUVANT [patent_app_type] => utility [patent_app_number] => 16/463357 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16463357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14893977 [patent_doc_number] => 20190290754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => VACCINE COMPOSITION COMPRISING HEPATITIS B VIRUS-LIKE PARTICLE AS ADJUVANT [patent_app_type] => utility [patent_app_number] => 16/463357 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16463357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622137 [patent_doc_number] => 20180362620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => HUMANIZED ANTI-EBOLA VIRUS GLYCOPROTEIN ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/821062 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28199 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15821062 [rel_patent_id] =>[rel_patent_doc_number] =>)